Solli, Vincenza
  
(2024)
Identification of outcome-oriented cut-offs for copy number alterations in multiple myeloma: predictive biomarkers with improved prognostic accuracy, [Dissertation thesis], Alma Mater Studiorum Università di Bologna. 
 Dottorato di ricerca in 
Oncologia, ematologia e patologia, 36 Ciclo.
  
 
  
  
        
        
        
  
  
  
  
  
  
  
    
  
    
      Documenti full-text disponibili:
      
    
  
  
    
      Abstract
      Aim of the present study was to develop a statistical approach to define the best cut-off Copy number alterations (CNAs) calling from genomic data provided by high throughput experiments, able to predict a specific clinical end-point (early relapse, 18 months) in the context of Multiple Myeloma (MM).
743 newly diagnosed MM patients with SNPs array-derived genomic and clinical data were included in the study.
CNAs were called both by a conventional (classic, CL) and an outcome-oriented (OO) method, and Progression Free Survival (PFS) hazard ratios of CNAs called by the two approaches were compared. 
The OO approach successfully identified patients at higher risk of relapse and the univariate survival analysis showed stronger prognostic effects for OO-defined high-risk alterations, as compared to that defined by CL approach, statistically significant for 12 CNAs.
Overall, 155/743 patients relapsed within 18 months from the therapy start. A small number of OO-defined CNAs were significantly recurrent in early-relapsed patients (ER-CNAs) - amp1q, amp2p, del2p, del12p, del17p, del19p -. Two groups of patients were identified either carrying or not ≥1 ER-CNAs (249 vs. 494, respectively), the first one with significantly shorter PFS and overall survivals (OS) (PFS HR 2.15, p<0001; OS HR 2.37, p<0.0001). The risk of relapse defined by the presence of ≥1 ER-CNAs was independent from those conferred both by R-IIS 3 (HR=1.51; p=0.01) and by low quality (< stable disease) clinical response (HR=2.59 p=0.004). Notably, the type of induction therapy was not descriptive, suggesting that ER is strongly related to patients’ baseline genomic architecture.
In conclusion, the OO- approach employed allowed to define CNAs-specific dynamic clonality cut-offs, improving the CNAs calls’ accuracy to identify MM patients with the highest probability to ER. As being outcome-dependent, the OO-approach is dynamic and might be adjusted according to the selected outcome variable of interest.
     
    
      Abstract
      Aim of the present study was to develop a statistical approach to define the best cut-off Copy number alterations (CNAs) calling from genomic data provided by high throughput experiments, able to predict a specific clinical end-point (early relapse, 18 months) in the context of Multiple Myeloma (MM).
743 newly diagnosed MM patients with SNPs array-derived genomic and clinical data were included in the study.
CNAs were called both by a conventional (classic, CL) and an outcome-oriented (OO) method, and Progression Free Survival (PFS) hazard ratios of CNAs called by the two approaches were compared. 
The OO approach successfully identified patients at higher risk of relapse and the univariate survival analysis showed stronger prognostic effects for OO-defined high-risk alterations, as compared to that defined by CL approach, statistically significant for 12 CNAs.
Overall, 155/743 patients relapsed within 18 months from the therapy start. A small number of OO-defined CNAs were significantly recurrent in early-relapsed patients (ER-CNAs) - amp1q, amp2p, del2p, del12p, del17p, del19p -. Two groups of patients were identified either carrying or not ≥1 ER-CNAs (249 vs. 494, respectively), the first one with significantly shorter PFS and overall survivals (OS) (PFS HR 2.15, p<0001; OS HR 2.37, p<0.0001). The risk of relapse defined by the presence of ≥1 ER-CNAs was independent from those conferred both by R-IIS 3 (HR=1.51; p=0.01) and by low quality (< stable disease) clinical response (HR=2.59 p=0.004). Notably, the type of induction therapy was not descriptive, suggesting that ER is strongly related to patients’ baseline genomic architecture.
In conclusion, the OO- approach employed allowed to define CNAs-specific dynamic clonality cut-offs, improving the CNAs calls’ accuracy to identify MM patients with the highest probability to ER. As being outcome-dependent, the OO-approach is dynamic and might be adjusted according to the selected outcome variable of interest.
     
  
  
    
    
      Tipologia del documento
      Tesi di dottorato
      
      
      
      
        
      
        
          Autore
          Solli, Vincenza
          
        
      
        
          Supervisore
          
          
        
      
        
          Co-supervisore
          
          
        
      
        
          Dottorato di ricerca
          
          
        
      
        
      
        
          Ciclo
          36
          
        
      
        
          Coordinatore
          
          
        
      
        
          Settore disciplinare
          
          
        
      
        
          Settore concorsuale
          
          
        
      
        
          Parole chiave
          Multiple Myeloma, early-relapse, biomarkers, copy numeber alteretion, genomic, cut-off,
          
        
      
        
          URN:NBN
          
          
        
      
        
      
        
          Data di discussione
          18 Marzo 2024
          
        
      
      URI
      
      
     
   
  
    Altri metadati
    
      Tipologia del documento
      Tesi di dottorato
      
      
      
      
        
      
        
          Autore
          Solli, Vincenza
          
        
      
        
          Supervisore
          
          
        
      
        
          Co-supervisore
          
          
        
      
        
          Dottorato di ricerca
          
          
        
      
        
      
        
          Ciclo
          36
          
        
      
        
          Coordinatore
          
          
        
      
        
          Settore disciplinare
          
          
        
      
        
          Settore concorsuale
          
          
        
      
        
          Parole chiave
          Multiple Myeloma, early-relapse, biomarkers, copy numeber alteretion, genomic, cut-off,
          
        
      
        
          URN:NBN
          
          
        
      
        
      
        
          Data di discussione
          18 Marzo 2024
          
        
      
      URI
      
      
     
   
  
  
  
  
  
  
    
      Gestione del documento: 
      
        